Competitor Analysis p38 MAPK Inhibitors

Date: November 22, 2010
Pages: 21
Price:
US$ 273.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C80E03B0CD5EN
Leaflet:

Download PDF Leaflet

Competitor Analysis p38 MAPK Inhibitors
The present Competitive Intelligence Report about p38 MAPK inhibitors used to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, COPD or pain, respectively, provides a competitor evaluation in the field of R&D projects with p38 MAPK inhibitors as of November 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation of p38 MAPK inhibitors suffered from side effects such as liver transaminase elevations, the newer inhibitors are more selective at targeting p38 and include non-ATP competitive inhibitors directed against the conformation epitope. The p38 MAPK covers a central role in the regulation of interleukin-1 beta (IL-1beta) and TNF-alpha signaling. Thus, inhibition of p38 MAPK would be expected to decrease the production of these cytokines.

About ten p38 MAPK inhibitors are in clinical phase I and II studies, with the first agent being administered by inhalation for respiratory diseases. The anti-inflammatory properties of p38 MAPK inhibitors are being evaluated in phase II clinical studies in psoriasis, patients at risk for cardiovascular disease/atherosclerosis, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD)/asthma and acute lung injuries. Further trials are assessing the value of p38 MAPK inhibition to treat pain.

The report includes a compilation of current active projects in research and development of p38 MAPK inhibitors. In addition, the report lists company-specific R&D pipelines of p38 MAPK inhibitors. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category/Therapeutic Area,
  • Indication,
  • R&D Stage and additional comments with a hyperlink leading to the source of information.

Index
  • p38 MAPK Inhibitors
  • p38 alpha MAPK Inhibitors
  • About La Merie

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top


Competitor Analysis: Notch Pathway Inhibitors US$ 110.00 Feb, 2010 · 10 pages
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors US$ 660.00 Jun, 2011 · 75 pages
Competitor Analysis: c-MET/HGF Inhibitors US$ 394.00 Jul, 2013 · 57 pages

Ask Your Question

Competitor Analysis p38 MAPK Inhibitors
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: